68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors

Launched by UNIVERSITY OF ALBERTA · May 12, 2021

Keywords

ClinConnect Summary

This clinical trial is studying a new imaging technique called 68Ga-HA-DOTATATE to help doctors find certain types of tumors known as somatostatin receptor positive tumors. These tumors can appear in various parts of the body, including the gastrointestinal tract, pancreas, and lungs. The goal of the study is to see how safe and effective this new imaging method is compared to older techniques. If you or a family member has been diagnosed with or is suspected to have one of these tumors, you might be eligible to participate in this trial.

To join the study, participants need to have a confirmed or suspected somatostatin receptor positive tumor and must have had a CT or MRI scan within the last six months. It's important that participants can give written consent and can lie still during the imaging process. However, individuals who weigh more than 225 kg, have difficulty with confined spaces, or have certain medical conditions may not be able to participate. If you choose to take part, you can expect to undergo PET imaging, which provides clearer pictures and better information about your tumor. This trial is currently recruiting participants, and your involvement could help improve how these tumors are diagnosed in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with known or clinically suspected somatostatin receptor positive tumors including but not limited to: gastrointestinal neuroendocrine tumors, pancreatic neuroendocrine tumors, pulmonary neuroendocrine tumors, neuroendocrine tumors - primary unknown, pheochromocytoma, paraganglioma, medullary thyroid cancer, medulloblastoma, meningioma
• • A standard clinical CT or MRI is obtained within 6 months of enrollment
• • Ability to provide written informed consent prior to participation in the study (participant or if required a legal medical decision maker)
• Exclusion Criteria:
• • Weight \> 225 kg (weight limit of the PET/CT scanner)
• • Inability to scan (ie. extreme claustrophobia) or inability to lie still for imaging
• • Any additional medical condition, serious inter-current illness, or other extenuating circumstance that, in the opinion of the investigator or attending department physician, may significantly interfere with study performance or interpretation
• • Previous allergic reaction to DOTATATE or somatostatin analogues
• • Lack of intravenous access